CTLA4 and neoplasm: Preliminary investigative findings in preclinical research suggest that cadonilimab’s selective accumulation within tumor tissues, in contrast to standard anti-PD-1 and anti-CTLA-4 antibodies, may contribute to an enhanced safety profile.